Business Strategies of Pharmaceutical Firms Research Paper by Kien
Business Strategies of Pharmaceutical Firms
A review of the business strategies of firms in the global drug sector.
# 153588
| 3,611 words
| 8 sources
| APA
| 2013
| 
Published
on Jul 04, 2013
in
Business
(Industries)
, Business
(International)
, Medical and Health
(Pharmacy)
$19.95
Buy and instantly download this paper now
Description:
This paper discusses the essential business practices of changing technology, organizational restructuring and international strategy in the context of pharmaceutical firms. The paper assesses the competitive influences of these practices in the pharmaceutical industry and provides a SWOT analysis of the industry. The paper concludes that the ability of a pharmaceutical firm to change its production technologies in response to the emerging needs in the drug sector is of paramount importance.
Outline:
Introduction
Discussion
Conclusion
Outline:
Introduction
Discussion
Conclusion
From the Paper:
"Numerous scientific changes which have significantly influenced discovery and production of new pharmaceutical drugs have rocked the global drug sector. These changes have been motivated by the rise in demand and need for innovative pharmaceutical drugs capable of addressing resistance and emerging health complications that have proven more difficult to treat with the existing drugs. In effect, pharmaceutical firms have shifted their resources and focus to production of novel drugs through increased research and development efforts (Geary, Conder, & Bishop, 2004:449)."Technological changes in the drug sector have compelled pharmaceutical firms to increasingly invest in production processes that utilize the most efficient technologies. For instance, drug firms dealing in Active Pharmaceutical Ingredients (API) have unanimously embraced the idea of increasing their investment in technology to aid their production processes and to enhance their competitive edge. The attractive opportunities offered by technological advancement in the active pharmaceutical ingredients field has enticed pharmaceutical firms such as Novasep and SAFC to make large investments in an effort to boost their market advantage (Arnum, 2011).
"Additionally, to ensure their strategic relevance in future, pharmaceutical firms have also strived to reduce the environmental footprints that are left by their products by adopting environment friendly production systems. For instance, Nativis pharmaceutical firm has development the signal therapy for use in treatment of cancer and other terminal complications which is environment friendly."
Sample of Sources Used:
- Arnum, P. V. (2011). The Changing Players and Supply Base for Generic Drugs. Pharmaceutical Technology Sourcing and Management , 7 (4).
- Chiesa, V. (2005). Industrial clusters in biotechnology. London: Imperial College Press.
- Gable, T., & Rogers, K. (2010, May 13). Nativis, Inc., a Paradigm Changing Drug Company, Presents Breakthrough Technology to Treat Brain Cancer and other Serious Diseases on CNBC World's The Eco Capitalist, Saturday, May 15th. Business Wire .
- Geary, T. G., Conder, G. A., & Bishop, B. (2004). The changing landscape of antiparasitic drug discovery for veterinary medicine. Trends in Parasitology , 20 (10), 449-455.
- Hume, N. (2007, November 23). Frazzled investors find solace in drugs. Financial Times .
Cite this Research Paper:
APA Format
Business Strategies of Pharmaceutical Firms (2013, July 04)
Retrieved May 28, 2023, from https://www.academon.com/research-paper/business-strategies-of-pharmaceutical-firms-153588/
MLA Format
"Business Strategies of Pharmaceutical Firms" 04 July 2013.
Web. 28 May. 2023. <https://www.academon.com/research-paper/business-strategies-of-pharmaceutical-firms-153588/>